EUVIMEDEUVIMED entdecken
ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease

Sung-Jin Hong, Yong-Joon Lee, Seung-Jun Lee, Bum-Kee Hong, Woong Chol Kang, Jong-Young Lee, Jin-Bae Lee, Tae-Hyun Yang, Junghan Yoon, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim und 5 weitere

JAMA · 04.04.2023 · 329 (13) · 1078

DOI: 10.1001/jama.2023.2487 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift JAMA, erschienen am 04.04.2023. Verfasst von Sung-Jin Hong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Cholesterol, LDL, Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipoproteinemias. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In patients with coronary artery disease, some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in low-density lipoprotein cholesterol (LDL-C). An alternative approach is to begin with moderate-intensity statins and titrate to a specific LDL-C goal. These alternatives have not been compared head-to-head in a clinical trial involving patients with known coronary artery disease.

Objective

To assess whether a treat-to-target strategy is noninferior to a strategy of high-intensity statins for long-term clinical outcomes in patients with coronary artery disease. Design, Setting, and Participants A randomized, multicenter, noninferiority trial in patients with a coronary disease diagnosis treated at 12 centers in South Korea (enrollment: September 9, 2016, through November 27, 2019; final follow-up: October 26, 2022).

Interventions

Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as the target, or high-intensity statin treatment, which consisted of rosuvastatin, 20 mg, or atorvastatin, 40 mg. Main Outcomes and Measures Primary end point was a 3-year composite of death, myocardial infarction, stroke, or coronary revascularization with a noninferiority margin of 3.0 percentage points.

Results

Among 4400 patients, 4341 patients (98.7%) completed the trial (mean [SD] age, 65.1 [9.9] years; 1228 females [27.9%]). In the treat-to-target group (n = 2200), which had 6449 person-years of follow-up, moderate-intensity and high-intensity dosing were used in 43% and 54%, respectively. The mean (SD) LDL-C level for 3 years was 69.1 (17.8) mg/dL in the treat-to-target group and 68.4 (20.1) mg/dL in the high-intensity statin group (n = 2200) ( P = .21, compared with the treat-to-target group). The primary end point occurred in 177 patients (8.1%) in the treat-to-target group and 190 patients (8.7%) in the high-intensity statin group (absolute difference, –0.6 percentage points [upper boundary of the 1-sided 97.5% CI, 1.1 percentage points]; P < .001 for noninferiority). Conclusions and Relevance Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization. These findings provide additional evidence supporting the suitability of a treat-to-target strategy that may allow a tailored approach with consideration for individual variability in drug response to statin therapy. Trial Registration ClinicalTrials.gov Identifier: NCT02579499

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLCoronary Artery DiseaseHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemiasRosuvastatin CalciumAtorvastatinAgedFemaleHumansMyocardial InfarctionStrokeTreatment OutcomeMaleMiddle Aged

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumAtorvastatin

Autor:innen und Institutionen

  • Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Gangnam Severance Hospital, Seoul, South Korea.
  • Gachon University College of Medicine, Incheon, South Korea.
  • Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Daegu Catholic University Medical Center, Daegu, South Korea.
  • Inje University Busan Paik Hospital, Busan, South Korea.

Zitieren

APA

Hong, S. J., Lee, Y. J., Lee, S. J., Hong, B. K., Kang, W. C., Lee, J. Y., Lee, J. B., Yang, T. H., Yoon, J., Ahn, C. M., Kim, J. S., Kim, B. K., Ko, Y. G., Choi, D., Jang, Y., Hong, M. K., & LODESTAR Investigators (2023). Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. JAMA, 329(13), 1078. https://doi.org/10.1001/jama.2023.2487

Vancouver

Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. JAMA. 2023;329(13):1078. doi:10.1001/jama.2023.2487

BibTeX
@article{Hong2023,
  author = {Hong, Sung-Jin and Lee, Yong-Joon and Lee, Seung-Jun and Hong, Bum-Kee and Kang, Woong Chol and Lee, Jong-Young and Lee, Jin-Bae and Yang, Tae-Hyun and Yoon, Junghan and Ahn, Chul-Min and Kim, Jung-Sun and Kim, Byeong-Keuk and Ko, Young-Guk and Choi, Donghoon and Jang, Yangsoo and Hong, Myeong-Ki and LODESTAR Investigators, LODESTAR Investigators},
  title = {Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {13},
  pages = {1078},
  doi = {10.1001/jama.2023.2487}
}
Kostenlos starten →